Is RXRX a good stock to invest today: Recursion Pharmaceuticals (ticker: RXRX) is a biotechnology company that focuses on using advanced technology and machine learning to discover and develop new drugs.
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to enhance drug discovery. Headquartered in Salt Lake City, Utah, the company aims to decode complex biological systems by integrating biology, chemistry, automation, data science, and engineering. As of February 20, 2025, RXRX is trading on the NASDAQ, and its stock price has garnered attention from investors intrigued by its AI-driven approach to pharmaceuticals. But is it a good stock to invest in today? Let’s break it down by examining its current stock price, financial performance, market trends, and risks.
As of the close of trading on February 20, 2025, the exact stock price of RXRX isn’t specified in real-time here, but recent trends can provide context. Based on widely available financial data up to this point, RXRX has experienced volatility typical of biotech stocks. For instance, its 52-week range has fluctuated between approximately $5.60 and $15.74, reflecting significant price swings. On February 14, 2025, posts on X noted the stock at $10.53, with a 24.12% increase that day, suggesting momentum. Assuming stability or slight movement since then, let’s estimate it’s hovering around $10-$11 as of today. Investors should verify the exact price via a financial platform like Yahoo Finance or Nasdaq for the latest figure.
This price reflects a market capitalization of roughly $3 billion, calculated by multiplying the current stock price by its outstanding shares (approximately 286.6 million). While this valuation is modest compared to giants like Moderna, it’s significant for a clinical-stage biotech without marketed products, raising questions about its investment potential.
Recursion Pharmaceuticals stands out by merging biotech with technology. Its Recursion Operating System (OS) uses AI to analyze vast biological and chemical datasets, aiming to identify drug candidates faster and more efficiently than traditional methods. The company’s pipeline includes therapies like REC-994 (Phase 2 for cerebral cavernous malformation), REC-2282 (Phase 2/3 for neurofibromatosis type 2), and REC-4881 (Phase 1b/2 for familial adenomatous polyposis), among others. These candidates target rare diseases and cancers, areas with high unmet needs.
Unlike revenue-generating pharma firms, Recursion is pre-commercial, relying on investor funding and partnerships (e.g., with Bayer, Roche, and Takeda) to fuel its research. This model promises innovation but carries inherent risks, as success hinges on clinical trial outcomes and regulatory approvals—both uncertain and years away.
Recursion’s financials reflect its early-stage status. In 2023, it reported $44.58 million in revenue, up 11.88% from $39.84 million in 2022, primarily from collaboration agreements. However, losses widened to $328.07 million, a 37% increase from 2022, driven by R&D expenses. As of its latest quarterly report (likely Q4 2024, released in early 2025), analysts expected an EPS of around -$0.34, with estimates ranging from -$0.70 to -$0.29, indicating ongoing unprofitability.
With a price-to-book ratio around 5.75x (higher than the biotech industry average of 4.77x), RXRX appears expensive relative to its tangible assets. Its negative price-to-earnings ratio (e.g., -6.89) is typical for a loss-making biotech, shifting focus to future potential rather than current earnings. Cash reserves and burn rate are critical here—Recursion has historically raised funds via stock offerings (e.g., $436 million IPO in 2021), but investors should monitor its liquidity to ensure it can sustain operations through clinical milestones.
Market sentiment on RXRX is mixed but leans cautiously optimistic. Analysts from firms like KeyBanc (Overweight, $16 target) and others peg a 12-month average price target around $10.33-$11, suggesting modest upside from a $10-$11 base. Ratings typically split between “Buy” (2/6 analysts) and “Hold” (4/6), per sources like TipRanks, reflecting uncertainty about its AI platform’s validation.
Investor enthusiasm spiked with high-profile backing—Cathie Wood’s ARK Invest holds a significant stake (valued at $216 million recently), and SoftBank filed a new position in February 2025. Nvidia’s $50 million investment in 2023 further ties RXRX to the AI hype cycle. Posts on X highlight bullish technicals (e.g., MACD and whale accumulation), yet skepticism persists about trial data, with some questioning if “safety” endpoints overshadow efficacy.
Recursion operates in a crowded biotech-AI intersection, competing with firms like Exscientia (which it acquired for $688 million in 2024), Insitro, and BenevolentAI. The Exscientia deal bolsters its chemical synthesis capabilities, potentially yielding $100 million in annual synergies, but integration risks remain. Broader industry trends favor AI in drug discovery—valued at $125 billion by 2028 per some forecasts—driven by the promise of reduced costs and timelines (traditional drug development takes 10-15 years and $1-2 billion per drug).
However, AI’s track record in biotech is nascent. While Recursion’s platform has identified candidates, no AI-derived drug from any company has yet reached market approval, tempering expectations. Competitors with stronger clinical progress or diversified pipelines might outpace RXRX if it stumbles.
Investing in RXRX carries substantial risks:
Clinical Risk: Recent Phase 2 data for REC-994 showed safety but mixed efficacy, disappointing some (e.g., X posts called it “sucked”). Failure to prove AI’s edge in trials could erode confidence.
Financial Risk: High cash burn and no near-term revenue mean reliance on dilutive funding.
Market Risk: Biotech stocks are volatile, and RXRX’s 14.11% daily volatility (per TradingView) amplifies this.
Regulatory Risk: FDA approval is years away, with no guarantee of success.
Hype Risk: AI-driven stocks can inflate beyond fundamentals, risking corrections.
A biotech veteran might argue RXRX’s valuation reflects hope, not results—a common pitfall in this sector.
So, is RXRX a good investment on February 20, 2025? It depends on your risk tolerance and horizon:
Bull Case: If Recursion’s AI platform delivers a breakthrough (e.g., REC-994 or REC-2282 advancing to Phase 3 with strong efficacy), the stock could soar—analysts’ high target of $16 implies 45-60% upside from $10-$11. Partnerships and acquisitions signal growth potential, and AI’s long-term promise could disrupt pharma.
Bear Case: Without “definitive wins” (as JPMorgan noted), RXRX risks languishing as an overhyped story stock. Ongoing losses, trial setbacks, and dilution could drag it below $6 (Jefferies’ low target), a 40-45% drop.
For a balanced view, RXRX is a speculative play. Its current price likely embeds optimism from AI buzz and institutional backing, but tangible progress lags. A “Hold” stance aligns with analyst consensus—accumulate on dips (e.g., $8-$9) but avoid chasing at peaks.
Recursion Pharmaceuticals (RXRX) embodies the high-risk, high-reward ethos of biotech investing. At $10-$11, it’s neither a screaming bargain nor grossly overvalued, sitting in a wait-and-see zone. Investors bullish on AI’s future in drug discovery might allocate a small portfolio slice (e.g., 2-5%), betting on long-term upside. Cautious types should watch for stronger clinical data or a pullback before diving in. As always, diversify, research deeply, and check real-time prices before acting—biotech’s rollercoaster spares no one.
When considering shares, indices, forex (foreign exchange) and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.
Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice.
